Evidence Hub

OS08.7.A neurosurgeons’ views on surgical trials for glioblastoma: attitudes, practices, and willingness to randomize

J. Duerinck, L. Lescrauwaet, P. Karschnia, R. Pérez Alfayate, M. Jenkinson, E. S. Molina, M. Simon, J. Gerritsen et al.

Neuro-Oncology, 2025

Abstract

The scarcity of randomized controlled trials (RCTs) in surgical neuro-oncology tends to limit the level of evidence for clinical practice. Specifically in the surgical treatment of glioblastoma, controversies on the optimal operative treatment remain. To evaluate the degree of equipoise and feasibility of surgical RCTs for Glioblastoma (GBM), we conducted an international survey of neurosurgeons, exploring neurosurgeons’ habits, opinions on current quality of evidence, and willingness to randomize patients with GBM into a surgical trial under specific circumstances.

We conducted a global survey among neurosurgeons. The survey was distributed through EORTC, EANS and CNS as well as several national neurosurgical societies. Chi-square test was used to assess the association between categorical variables.

In total, 328 neurosurgeons from 38 countries and 5 continents responded. Most participants (83.2%) worked in academic centers. 81.7% were male. All career stages (defined as years since completing training) were well represented in the survey, as were individual volumes of brain tumors operated yearly in current practice. Neuronavigation (98.5%), intraoperative neuromonitoring (80.2%), fluorescence (80.6%) and intraoperative ultrasound (60.1%) are the most frequently used technological aids. A majority of neurosurgeons (60.4%) appear to hold supramarginal resection(SM) as the optimal goal in GBM surgery, while 37.8% maximally aim to achieve a complete resection of enhancing…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free